Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2001

View Archived Issues

TheraMed now called MaxCyte

FDA and EMEA accept Amevive filing for psoriasis

Modex acquires rights to novel small molecule to protect against radiation-induced skin damage

Revotar enters licensing agreement with Fraunhofer Institute for MIF

Phase II trial of Heptazyme for hepatitis C initiated

Study using Imavist for improved detection of prostate cancer set to begin

IntraBiotics presents promising results for iseganan in treating ventilator-associated pneumonia

Companies collaborate on the development of novel Alzheimer's vaccine

Endogenous brain cannabinoid is neuroprotective in mice with traumatic brain injury

Adenosine A2A receptor as a new target for antidepressant therapy

Phase I clinical trial of Esperion's RLT peptide to commence at Mayo Clinic

Cell Pathways encouraged by rapid progress made in clinical studies of CP-461 for CLL

TA-0201: a promising new drug for cardiovascular diseases

Second phase I/II clinical trial of Levulan PDT begins for treatment of Barrett's esophagus

Orally active, metabolically stable muscarinic M2 antagonist emerges from Schering-Plough screening

ICAgen seeks partners for pain management program

Orphan Medical submits amended NDA to FDA for Xyrem

Novel AEDs validated preclinically available for licensing from ICAgen

Xenova terminates TA-HSV development, DISC-PRO studies continue

Clinically used pain medication now claimed for IBS

Novel combinations claimed by Merck Frosst for depression and anxiety

Oxamide-based inhibitors of IMPDH under study at Roche

Dainippon compounds with benzodiazepine receptor subtype selectivity

Asahi Glass describes novel antiglaucoma difluoroprostaglandins

Preparation and use of new beta3-adrenoceptor agonists covered in recent patent

Thyroid hormone receptor ligands in development at Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 26, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026